Clinical Trials Logo

Medical Oncology clinical trials

View clinical trials related to Medical Oncology.

Filter by:

NCT ID: NCT02457351 Completed - Medical Oncology Clinical Trials

Roniciclib (BAY 1000394) Drug-Drug Interaction (DDI) Study

Start date: July 2015
Phase: Phase 1
Study type: Interventional

To evaluate the effect of itraconazole, a strong CYP3A4 inhibitor, on the pharmacokinetics of roniciclib in cancer patients. To assess safety and tolerability of roniciclib dosing when administered with and without itraconazole in cancer patients

NCT ID: NCT02439346 Terminated - Medical Oncology Clinical Trials

Phase I Dose Escalation and Expansion of Oral BAY 1143269 in Combination With Intravenous Docetaxel

Start date: June 15, 2015
Phase: Phase 1
Study type: Interventional

Determine the safety, tolerability, maximum tolerated dose (MTD), pharmacokinetics (PK), and/or recommended Phase II dose (RP2D) of oral BAY 1143269 given alone or in combination with intravenous (IV) docetaxel in subjects with advanced solid tumors.

NCT ID: NCT02427490 Completed - Palliative Care Clinical Trials

A Problem-Solving Intervention for Family Caregivers in Palliative Oncology

Start date: April 2015
Phase: N/A
Study type: Interventional

In congruence with the National Cancer Institute's commitment to supporting families of individuals with cancer across the full disease trajectory, the investigators seek to examine the feasibility of a technologically-mediated problem-solving intervention designed to improve the quality of life and decrease the psychological distress of family caregivers of cancer patients receiving outpatient palliative care. Investigators involved in this mixed methods pilot study will collect and analyze both quantitative and qualitative data, which will subsequently inform a large-scale randomized clinical trial of the problem-solving intervention.

NCT ID: NCT02368951 Terminated - Medical Oncology Clinical Trials

Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)

Start date: March 24, 2015
Phase: Phase 1
Study type: Interventional

To evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-FGFR2 antibody drug conjugate BAY1187982 in subjects with advanced solid tumors known to express fibroblast growth factor receptor 2 (FGFR2)

NCT ID: NCT02366949 Completed - Medical Oncology Clinical Trials

Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel

Start date: February 27, 2015
Phase: Phase 1
Study type: Interventional

Determine the safety, tolerability, maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of oral BAY1217389 given in combination with intravenous (IV) paclitaxel using an intermittent dosing schedule (2 days on / 5 days off) in subjects with advanced malignancies.

NCT ID: NCT02357953 Completed - Medical Oncology Clinical Trials

Transpulmonary Thermodilution Using an Implented Central Venous Access Port

ThermoD-PAC
Start date: October 2012
Phase: N/A
Study type: Observational

Perioperative hemodynamic optimization requires monitoring adapted to the risks of the surgery and the patient. The investigators currently use a local hemodynamic protocol based on the data of the literature. According to this protocol, specific patients may require cardiac index and central venous oxygen saturation monitoring. the investigators chose to monitor the cardiac index (CI) with the transpulmonary thermodilution technique (TPTD) (PiCCO, Pulsion Medical System, Munich, Allemagne). The technique is based on the injection of a cooled bolus of saline into a central vein with a central venous catheter (CVC). The variation of temperature is measured with an arterial femoral catheter and allows the assessment of the cardiac output according to Stewart-Hamilton's theory. Many studies showed the reliability of this technique (Bein J Cardio Thorac Vasc Anesth 2004, Buhre Cardio thorac vasc anesth 1999, Felbinger J Clin ANesth 2005, Felbinger TW J Clin Anetsh 2002, Godie O Ann Thorac Surg 1999). In our institute, most of the patients are fitted with a port for chemotherapy or parenteral nutrition. When PiCCO monitoring is necessary, a central venous catheter is inserted on the opposite side of the permanent implantable venous port. Indeed, insertion of the CVC can be more difficult because of the port. It may be interesting to use the port for TPTD in order to avoid the insertion of a new CVC. This would be possible only if the measurement of CI by the port was as reliable as the classical measurement with a CVC. The aim of this study was to assess whether measurement of the CI by TPTD was possible and reliable via the port. The investigators conducted a prospective study comparing the measurement of the CI by TPTD before and after fluid challenge via the port versus the CVC.

NCT ID: NCT02327806 Not yet recruiting - Medical Oncology Clinical Trials

The Effect of Pullsed Magnetic Field Induction on Improving the Forearm Tissue Muscle Performance

Start date: January 2015
Phase: N/A
Study type: Interventional

Pulsed electromagnetic field therapy (PEMFT) is a reparative technique most commonly used in the field of orthopedics for the treatment of non-union fractures. The aim is to test the effect of the magnetic induction on brute force of treated muscle in oncological patients. Oncology patients were chosen as we assume that the ipmrovement will be more noticable in oncology patients than in a non-oncology, healthy subjects.

NCT ID: NCT02253420 Completed - Medical Oncology Clinical Trials

COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients

Start date: October 8, 2014
Phase: Phase 1
Study type: Interventional

To evaluate the effect of itraconazole or rifampin on the absorption, distribution, metabolism and elimination of COPANLISIB (BAY80-6946). To evaluate the effect of copanlisib on QT/QTc intervals and left ventricular ejection fraction as parameters of cardiovascular safety.

NCT ID: NCT02138812 Terminated - Medical Oncology Clinical Trials

Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel

Start date: May 9, 2014
Phase: Phase 1
Study type: Interventional

Determine the safety, tolerability, maximum tolerated dose (MTD), and recommended Phase II dose (RP2D) of BAY1161909 in combination with paclitaxel in subjects with advanced malignancies.

NCT ID: NCT01409135 Completed - Neoplasms Clinical Trials

A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4

Start date: July 11, 2011
Phase: Phase 1
Study type: Interventional

A study examining the safety of AGS-22M6E or ASG-22CE administered as monotherapy therapy in subjects with malignant solid tumors that express Nectin-4.